These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38163440)

  • 1. Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations.
    Lu X; Yang R; Chen Y; Chen D
    Clin Mol Hepatol; 2024 Jul; 30(3):582-584. PubMed ID: 38163440
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.
    Polyzos SA; Mantzoros CS
    Metabolism; 2024 Aug; 157():155936. PubMed ID: 38763229
    [No Abstract]   [Full Text] [Related]  

  • 3. The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?
    Boutari C; Athyros VG
    Angiology; 2024 Mar; 75(3):205-207. PubMed ID: 37691291
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
    Zhou CC; Yang X; Hua X; Liu J; Fan MB; Li GQ; Song J; Xu TY; Li ZY; Guan YF; Wang P; Miao CY
    Br J Pharmacol; 2016 Aug; 173(15):2352-68. PubMed ID: 27174364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic steatosis induced in C57BL/6 mice by a non-ß oxidizable fatty acid analogue is associated with reduced plasma kynurenine metabolites and a modified hepatic NAD
    Berge RK; Cacabelos D; Señarís R; Nordrehaug JE; Nygård O; Skorve J; Bjørndal B
    Lipids Health Dis; 2020 May; 19(1):94. PubMed ID: 32410680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.
    Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M
    Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAD
    Dall M; Hassing AS; Treebak JT
    J Physiol; 2022 Mar; 600(5):1135-1154. PubMed ID: 33932956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis.
    Pham TX; Bae M; Kim MB; Lee Y; Hu S; Kang H; Park YK; Lee JY
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2451-2463. PubMed ID: 31195117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.
    Tsutsumi T; Nakano D; Kawaguchi M; Takahashi H; Kawaguchi T
    Clin Mol Hepatol; 2024 Apr; 30(2):266-268. PubMed ID: 38471499
    [No Abstract]   [Full Text] [Related]  

  • 11. Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella.
    Noureddin M; Wei L; Castera L; Tsochatzis EA
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):9-11. PubMed ID: 37848118
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
    Zabihi NA; Pirro M; Johnston TP; Sahebkar A
    Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    J Hepatol; 2024 Jul; 81(1):e20-e21. PubMed ID: 38906627
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges.
    Allen AM; Pose E; Reddy KR; Russo MW; Kamath PS
    Gastroenterology; 2024 Feb; 166(2):229-234. PubMed ID: 37949246
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial.
    Vrentzos E; Ikonomidis I; Pavlidis G; Katogiannis K; Korakas E; Kountouri A; Pliouta L; Michalopoulou E; Pelekanou E; Boumpas D; Lambadiari V
    Cardiovasc Diabetol; 2024 Jul; 23(1):245. PubMed ID: 38987784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.